Shares of Neos Therapeutics Inc. (NASDAQ:NEOS) rose 4.4% during trading on Friday . The stock traded as high as $7.70 and last traded at $7.59, with a volume of 109,619 shares changing hands. The stock had previously closed at $7.27.

NEOS has been the topic of several research reports. BMO Capital Markets initiated coverage on shares of Neos Therapeutics in a research report on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price target on the stock. Zacks Investment Research lowered shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Royal Bank Of Canada lowered their price target on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 17th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $21.75.

The stock has a 50 day moving average price of $8.86 and a 200 day moving average price of $9.65. The stock’s market cap is $117.79 million.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.16) by $0.49. The company had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $1.48 million. Equities research analysts forecast that Neos Therapeutics Inc. will post ($5.38) EPS for the current year.

In related news, Director Alan L. Heller purchased 10,000 shares of the company’s stock in a transaction on Thursday, May 19th. The shares were bought at an average cost of $7.61 per share, for a total transaction of $76,100.00. Following the transaction, the director now owns 379,888 shares of the company’s stock, valued at $2,890,947.68. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gregory J. Robitaille purchased 7,442 shares of the company’s stock in a transaction on Wednesday, May 18th. The shares were bought at an average price of $7.55 per share, for a total transaction of $56,187.10. Following the completion of the transaction, the director now directly owns 55,677 shares in the company, valued at approximately $420,361.35. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP increased its position in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned about 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent quarter.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.